JARED ARNETT: Open Payments
NPI 1053703488 · STE GENEVIEVE, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,353 in 64 payments from 14 companies in 2025. Trend: 2023 $705 · 2024 $729 · 2025 $1,353
Food & beverage: $1,241Education: $111
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 10 | $267 |
| Teva Pharmaceuticals USA, Inc. | 7 | $237 |
| ABBVIE INC. | 16 | $158 |
| Janssen Pharmaceuticals, Inc | 8 | $148 |
| Neurocrine BioSciences, Inc. | 3 | $90 |
| Vanda Pharmaceuticals Inc. | 3 | $87 |
| Otsuka America Pharmaceutical, Inc. | 3 | $81 |
| E.R. Squibb & Sons, L.L.C. | 4 | $80 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $76 |
| Lundbeck LLC | 2 | $38 |
Products named: ARISTADA, VRAYLAR, REXULTI, UZEDY, LYBALVI, INVEGA SUSTENNA, INGREZZA, COBENFY.
Industry payments across MO — which companies pay providers there.
